Multiple Myeloma

Results from a phase 3 study of a circularly permuted tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) combined with thalidomide and dexamethasone showed this was a safe and effective treatment for patients with relapsed/refractory multiple myeloma (RRMM), including those with a poor prognosis.
The GMMG-HD6 study, an ongoing phase 3, randomized, open-label, multicenter trial, examines the effect of bortezomib, lenalidomide, and dexamethasone (VRD) with or without the addition of elotuzumab as induction therapy for newly diagnosed transplant-eligible patients with multiple myeloma (MM).
Patients with light chain (AL) amyloidosis who were previously treated found encouraging efficacy and a good safety profile based on preliminary results from a phase 2 study of isatuximab.
According to the IKEMA study interim analysis, isatuximab (Isa) plus carfilzomib and dexamethasone (Isa-Kd) resulted in a clinically meaningful improvement in depth of response; more patients reached minimal residual disease (MRD)-negative status when compared with those patients who received carfilzomib and dexamethasone alone.
Both this retrospective analysis of the ICARIA-MM study data and the phase 1b TCD14079 study data aimed to evaluate the efficacy of isatuximab (Isa) with pomalidomide-dexamethasone (Pd) in patients with relapsed/refractory multiple myeloma (RRMM) with the gain(1q21) chromosomal abnormality.
The ongoing GMMG-Concept trial is a phase 2, multicenter, investigator-initiated, open-label trial examining the induction, consolidation, and maintenance treatment of the 4-drug combination of isatuximab plus carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in patients newly diagnosed with high-risk multiple myeloma (MM); this includes both transplant-eligible and non–transplant-eligible patients.
The year 2020 was an unprecedented year, bringing significant changes in the practice of medicine and knowledge sharing at scientific forums. National and international meetings, such as the European Hematological Association (EHA) and the American Society of Hematology (ASH), pivoted to facilitate the dissemination of information regarding cutting-edge research and treatment advances in a virtual format.
Based on interim results from the STOMP study in patients with relapsed/refractory multiple myeloma (RRMM) who are heavily pretreated, the combination of selinexor, pomalidomide, and dexamethasone appears to offer relatively high overall response rates (ORRs) and encouraging progression-free survival (PFS).
In patients with relapsed/refractory multiple myeloma (RRMM), preliminary results from this phase 1b/2 study of cobimetinib alone or plus venetoclax, with or without atezolizumab show manageable toxicity, moderate efficacy overall, and higher efficacy for those with t(11;14).
An ongoing phase 1/2, nonrandomized, multicenter study is exploring the safety profile, efficacy, and pharmacokinetics of adding daratumumab to venetoclax and dexamethasone with or without bortezomib for patients with relapsed/refractory multiple myeloma (RRMM) who have a t(11;14) abnormality.
Page 2 of 5
Results 11 - 20 of 41